Menu Search
Equities

Bioventix PLC

51B:DEU

Bioventix PLC

Actions
  • Price (EUR)43.80
  • Today's Change0.80 / 1.86%
  • Shares traded0.00
  • 1 Year change+5.29%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function, and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.

  • Revenue in GBP (TTM)13.61m
  • Net income in GBP8.10m
  • Incorporated2003
  • Employees16.00
  • Location
    Bioventix PLC7 Romans Business Park, East StreetFARNHAM GU9 7SXUnited KingdomGBR
  • Phone+44 125 272 8001
  • Fax+44 125 272 8002
  • Websitehttps://www.bioventix.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.